Paul Giannasca
No más puestos en curso
Historial de carrera de Paul Giannasca
Antiguos cargos conocidos de Paul Giannasca.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Corporate Officer/Principal | - | - |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 31/03/2011 | - |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - | - |
Formación de Paul Giannasca.
| Fairleigh Dickinson University | Undergraduate Degree |
| University of Massachusetts | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Reino Unido | 2 |
Operativa
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
OraVax, Inc.
OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Health Technology |
- Bolsa de valores
- Insiders
- Paul Giannasca
- Experiencia
